2011 Q4 Form 10-Q Financial Statement

#000110465911059341 Filed on November 01, 2011

View on sec.gov

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-60186000	USD
	us-gaap	Interest Expense InterestExpense	22000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	294000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-60458000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
CY2011Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8422000	USD
CY2011Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	134000	USD
CY2011Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2496000	USD
CY2011Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4517000	USD
CY2011Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71233155	shares
CY2011Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71233155	shares
CY2011Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2011Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2011Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275865000	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	257964000	USD
CY2011Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-635620000	USD
CY2011Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-22000	USD
CY2011Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	893535000	USD
CY2011Q3	us-gaap	Common Stock Value CommonStockValue	71000	USD
CY2011Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	123000	USD
CY2011Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9356000	USD
CY2011Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1275000	USD
CY2011Q3	us-gaap	Assets Assets	275865000	USD
CY2011Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2050000	USD
CY2011Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5223000	USD
CY2011Q3	us-gaap	Assets Current AssetsCurrent	268592000	USD
CY2011Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2910000	USD
CY2011Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	247000000	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18682000	USD
CY2011Q3	us-gaap	Contracts Revenue ContractsRevenue	4355000	USD
CY2010Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52769000	shares
CY2010Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52127000	shares
CY2010Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.96
CY2010Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.97
CY2010Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52271184	shares
CY2010Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52271184	shares
CY2010Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2010Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2010Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2010Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	186695000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	166131000	USD
CY2010Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-575434000	USD
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-38000	USD
CY2010Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	741551000	USD
CY2010Q4	us-gaap	Common Stock Value CommonStockValue	52000	USD
CY2010Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	137000	USD
CY2010Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9056000	USD
CY2010Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	45000	USD
CY2010Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11326000	USD
CY2010Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	755000	USD
CY2010Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4357000	USD
CY2010Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4811000	USD
CY2010Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1403000	USD
CY2010Q4	us-gaap	Assets Assets	186695000	USD
CY2010Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2235000	USD
CY2010Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4534000	USD
CY2010Q4	us-gaap	Assets Current AssetsCurrent	179926000	USD
CY2010Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2631000	USD
CY2010Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	168418000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8877000	USD
CY2011Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71226000	shares
CY2011Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71226000	shares
CY2011Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2011Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17931000	USD
CY2011Q3	us-gaap	Interest Expense InterestExpense	4000	USD
CY2011Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	114000	USD
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18041000	USD
CY2011Q3	us-gaap	Costs And Expenses CostsAndExpenses	22396000	USD
CY2011Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5080000	USD
CY2010Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	50433000	USD
CY2010Q3	us-gaap	Interest Expense InterestExpense	15000	USD
CY2010Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	90000	USD
CY2010Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	50358000	USD
CY2010Q3	us-gaap	Costs And Expenses CostsAndExpenses	21924000	USD
CY2010Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5530000	USD
CY2010Q3	us-gaap	Contracts Revenue ContractsRevenue	72282000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60660000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60660000	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
	us-gaap	Costs And Expenses CostsAndExpenses	65208000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15677000	USD
	us-gaap	Contracts Revenue ContractsRevenue	4750000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52536000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52022000	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.06
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	55129000	USD
	us-gaap	Interest Expense InterestExpense	70000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	213000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	54986000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	70014000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19380000	USD
	us-gaap	Contracts Revenue ContractsRevenue	125000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-29448000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2632000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	148189000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	175005000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	36475000	USD
	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	3234000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1827000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2653000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-164000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-194000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-471000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12635000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	924000	USD
	us-gaap	Interest Paid InterestPaid	20000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	9805000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	141210000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	141876000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	666000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-80684000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2118000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	234056000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	312622000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-50721000	USD
	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	-286000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1861000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-294000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-128000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-185000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	279000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10127000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1429000	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">2.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">Basis of Presentation</font></b></p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Our accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information and pursuant to the instructions to Form&nbsp;10-Q and Article&nbsp;10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include all normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year. The balance sheet at December&nbsp;31, 2010 has been derived from audited financial statements at that date, but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2010.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</font></p></td></tr></table>
CY2010Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22058000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14717000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	7341000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	314000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1193000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">1.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">Nature of Operations</font></b></p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">We were incorporated in the state of Delaware on June&nbsp;14, 1996. We are engaged in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.</font></p></td></tr></table>
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2011
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2011-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001034842
	dei	Entity Registrant Name EntityRegistrantName	RIGEL PHARMACEUTICALS INC
CY2011Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71243478	shares
	us-gaap	Interest Paid InterestPaid	70000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	879000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	0	USD

Files In Submission

Name	View Source	Status
0001104659-11-059341-index-headers.html	Edgar Link	pending
0001104659-11-059341-index.html	Edgar Link	pending
0001104659-11-059341.txt	Edgar Link	pending
0001104659-11-059341-xbrl.zip	Edgar Link	pending
a11-25716_110q.htm	Edgar Link	pending
a11-25716_1ex10d35.htm	Edgar Link	pending
a11-25716_1ex31d1.htm	Edgar Link	pending
a11-25716_1ex31d2.htm	Edgar Link	pending
a11-25716_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rigl-20110930.xml	Edgar Link	completed
rigl-20110930.xsd	Edgar Link	pending
rigl-20110930_cal.xml	Edgar Link	unprocessable
rigl-20110930_def.xml	Edgar Link	unprocessable
rigl-20110930_lab.xml	Edgar Link	unprocessable
rigl-20110930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending